Blenrep (Belantamab Mafodotin)

  • Brand Name: Blenrep
  • Innovator Brand Name: Blenrep
  • API: Belantamab Mafodotin-blmf
  • Dosage Form: 1 Vial (Per Box)
  • Strength: 100mg
  • Manufacturer Name: GlaxoSmithKline
Get Price

Description

Blenrep Uses:

Blenrep (Belantamab Mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate used for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously taken at least four therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Dosage: The recommended dosage of Blenrep is 2.5 mg/kg of actual body weight, should be administered as an intravenous infusion over approximately 30 minutes once every three weeks until the disease is progressive or unacceptable toxicity occurs.

Side Effects:  The most commonly reported belantamab mafodotin side effects (incidence ≥20%) include:

  • Nausea
  • Blurred vision
  • Pyrexia
  • Fatigue
  • Decreased visual acuity
  • Infusion-related reactions
  • Keratopathy (corneal epithelium change on eye exam)

Warnings and Precautions:

  • Perform an ophthalmic exam prior to initiation of blenrep 100 mg and during treatment.
  • Patients with blenrep are advised to use preservative-free lubricant eye drops and avoid contact lenses unless directed by an ophthalmologist.
  • Perform complete blood cell counts at baseline and during treatment with blenrep drug as clinically indicated.
  • Monitor patients with Belantamab Mafodotin-blmf for infusion-related reactions.
  • Based on its mechanism of action, blenrep uses can be responsible for causing fetal harm if administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F) and it targets actively dividing cells.
  • Because of the risk for serious adverse reactions in the breastfed child, advise women not to breastfeed while on blenrep dosing and for 3 months after the last dose.

More info

Storage: Store Belantamab Mafodotin-blmf vials refrigerated at temperature 36°F to 46°F (2°C to 8°C). Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the BLENREP at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the BLENREP Injections. Buying Procedure: In order to buy BLENREP, you can contact us at our TOLL-FREE Number 1800 889 1064 or on WhatsApp Number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusions: Belantamab mafodotin therapy was well tolerated and demonstrated rapid deep as well as durable responses in heavily pre-treated patients with relapsed/refractory multiple myeloma. With additional follow-up, more complete responses and considerably longer Progression Free Survival was noted in the final analysis in comparison to interim analysis.

FAQ

What is Blenrep? Blenrep is a prescription medicine used for the treatment of adults with multiple myeloma who have previously received at least 4 drugs to treat multiple myeloma, and their cancer has recurrence or did not respond to prior treatment. What does Blenrep contain as an active substance? The medication Blenrep specifically contains the active substance Belantamab Mafodotin. How is Belantamab Mafodotin administered? Belantamab Mafodotin is administered intravenously. How much does blenrep cost? The blenrep price in India usually can vary depending on the wholesaler/pharmacy you visit. Blenrep is available as a brand name drug only, a generic version is not yet available. What is the best price for Belantamab Mafodotin? Please contact Toll-free: +91 1800 889 1064|+919310090915 for belantamab mafodotin price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Blenrep (Belantamab Mafodotin) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Blenrep (Belantamab Mafodotin), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.
×